Products
Online Inquiry
SU5402
Cat. No.:
OB0225WX-2697
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
SU5402 is a multi-targeted receptor tyrosine kinase inhibitor with IC50 values of 20 nM for VEGFR2, 30 nM for FGFR1, and 510 nM for PDGF-R-beta.
Synonym:
215543-92-3; su5402; SU 5402; SU-5402; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; 2-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrole-3-propanoic acid; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid; 3-{4-methyl-2-[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl}propanoic acid; (Z)-3-[(3-(2-Carboxyethyl)-4-methylpyrrol-2-yl)methylidenyl]indolin-2-one; 2-[(1,2-Dihydro-2-oxo-3H-indol-3-yl idene)methyl]-4-methyl-1H-pyrrole-3-propanoic acid; 3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; 3-(4-methyl-2-{[(3Z)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-{4-methyl-2-[(Z)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl}propanoic acid
CAS No.:
215543-92-3
Compound CID:
5289418
Formula:
C17H16N2O3
Formula Weight:
296.32
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
SU5402 is utilized in developmental biology as a multi-target tyrosine kinase inhibitor to investigate the disruption of FGF, VEGF, and PDGF signaling during organogenesis and vascular development.
Library Information
Target:
FGFR; PDGFR; VEGFR
Receptor:
FGFR; PDGFR; VEGFR
Pathways:
Protein tyrosine kinase
Plate Number:
L6700-09
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
59 mg/mL; 199.11 mM
ALogP:
2.723
HBA_Count:
2
HBD_Count:
2
Rotatable Bond:
4





